Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Income from Continuing Operations (2022 - 2025)

Zentalis Pharmaceuticals (ZNTL) has 4 years of Income from Continuing Operations data on record, last reported at 26691000.0 in Q3 2025.

  • For Q3 2025, Income from Continuing Operations rose 33.54% year-over-year to 26691000.0; the TTM value through Sep 2025 reached 149316000.0, up 16.74%, while the annual FY2024 figure was 165867000.0, 39.97% up from the prior year.
  • Income from Continuing Operations reached 26691000.0 in Q3 2025 per ZNTL's latest filing, up from 26874000.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 10040000.0 in Q1 2024 and bottomed at 98860000.0 in Q2 2023.
  • Average Income from Continuing Operations over 4 years is 50988866.67, with a median of 52129000.0 recorded in 2022.
  • Peak YoY movement for Income from Continuing Operations: surged 116.47% in 2024, then crashed 580.87% in 2025.
  • A 4-year view of Income from Continuing Operations shows it stood at 48162000.0 in 2022, then decreased by 26.53% to 60939000.0 in 2023, then grew by 22.1% to 47472000.0 in 2024, then skyrocketed by 43.78% to 26691000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Income from Continuing Operations were 26691000.0 in Q3 2025, 26874000.0 in Q2 2025, and 48279000.0 in Q1 2025.